Join StocksJar.com -Get 7 Days Free trial

Stryker Corporation (SYK) Stock Price & AI Analysis

NASDAQ
USA

$389.76

$0.14
(0.16%)

Subscribe to get
AI Score

  • Market Cap 148.58B
  • Volume 702,618
  • Avg Volume 1.18M
  • Target Price $379.91
  • 52W Range 285.79 - 398.20
  • RSI (14) 60.8
  • Beta 0.95
  • PEG Ratio 3.94
  • SMA 20 1.15
  • SMA 50 5.45
  • SMA 200 11.31
  • Insider Owner 6.27%
  • Insider Trans -2.08%
  • Institution Owner 80.57%
  • Institution Trans 1.26%
  • Short Interest 4.77%
  • EPS next Y 12.24

Stryker Corporation Company Profile

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.
Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Stryker Corporation | Latest news

Stryker Gains 30.2% Year to Date: What's Driving the Stock?

Stryker Gains 30.2% Year to Date: What's Driving the Stock?

Stryker Corporation SYK has witnessed substantial gains in the year-to-date period. Shares of the...

Zacks - 12 hours ago

Stryker Corporation (SYK): A Bull Case Theory

Stryker Corporation (SYK): A Bull Case Theory

We came across a bullish thesis on Stryker Corporation (SYK) on Substack by Kontra Investment Xchange. In this article, we will summarize the bulls’...

Insider Monkey - 2 days ago

Here’s Mar Vista Strategic Growth Strategy’s Investment Thesis for Stryker...

Here’s Mar Vista Strategic Growth Strategy’s Investment Thesis for Stryker...

Mar Vista Investment Partners, LLC, an investment management company, released the “Strategic Growth...

Insider Monkey - 3 days ago

Dynamic Technology Lab Private Ltd Purchases New Shares in Stryker Co....

Dynamic Technology Lab Private Ltd Purchases New Shares in Stryker Co....

Dynamic Technology Lab Private Ltd acquired a new position in Stryker Co. (NYSE:SYK – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and ...

ETF DAILY NEWS - 5 days ago

The Zacks Analyst Blog Highlights Amazon.com, Stryker, Lam Research and ImmuCell

The Zacks Analyst Blog Highlights Amazon.com, Stryker, Lam Research and ImmuCell

Stocks recently featured in the blog include: Amazon.com, Inc. AMZN, Stryker Corp. SYK, Lam Research...

Zacks - 2 days ago

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024,...

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024,...

Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to “Attractive,”...

Benzinga - 3 days ago

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MD

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MD

Aptose Biosciences Inc. (“Aptose” or the “Company”) ( APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic ...

Guru Focus - 3 days ago

Pyroptotic cell corpses are crowned with F-actin-rich filopodia that engage...

Pyroptotic cell corpses are crowned with F-actin-rich filopodia that engage...

Pyroptotic cell death results in inflammation. Here the authors find that F-actin-rich structures formed during macrophage pyroptosis persist after cell death to activate dendritic cells.

Nature - 2 days ago